Acasti Pharma (ACST) Reports Q4 Loss of $0.02

Acasti Pharma (NASDAQ: ACST) reported Q4 EPS of ($0.02), versus ($0.02) reported last year.

Acasti is now corresponding with the FDA to determine next steps in the clinical development of CaPre®, and obtain the required authorizations to proceed with such steps, including initiating a Phase III clinical trial. Such correspondence is meant to allow the FDA to provide feedback on Acasti's submissions and to answer specific questions on such submissions. Prior to a final response from the FDA, any exchange with them can take the form of written correspondence, discussions and potentially face-to-face meetings. The Company is working to respond to FDA feedback and will be working with them to determine resolution and direction needed to advance to Phase III.

For earnings history and earnings-related data on Acasti Pharma (ACST) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c